Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy

Chimeric antigen receptor (CAR) T cells have demonstrated remarkable anti-tumor efficacy against hematological malignancies, such as leukemia and lymphoma. However, patients treated with CAR-T cells frequently experience cytokine release syndrome (CRS), one of the most life-threatening adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales: Balagopal, Srinivas, Sasaki, Koichi, Kaur, Pooja, Nikolaidi, Maria, Ishihara, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518648/
https://www.ncbi.nlm.nih.gov/pubmed/35912720
http://dx.doi.org/10.1039/d2tb00592a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518648/
https://www.ncbi.nlm.nih.gov/pubmed/35912720
http://dx.doi.org/10.1039/d2tb00592a

Ejemplares similares